Curis, Inc. (CRIS) Stock Price & Analysis
Curis, Inc. (CRIS) is trading at USD 0.39, down 3.06% today, as of October 23, 2026 at 14:03 UTC (US market open; quotes may be delayed), according to Nexqual market data.
CRIS last closed at USD 0.39; today's session has ranged USD 0.39–0.42 on volume of 22,477 shares. Market capitalization is —, with a 52-week range of USD 0.33–33.6 (NCM). Source: Nexqual, retrieved October 23, 2026 at 14:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CRIS.md
Key facts (CRIS)
- Last four reported quarters (through Jun 30, 2026): revenue $4.3M, net income -$21.2M (-490.3% margin) (SEC filings).
- 1 of 80 tracked superinvestors hold CRIS (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Total return with dividends: 1Y -98.8% vs S&P 500 +14.4%; 5Y -100.0% vs S&P 500 +77.0%.
- Next earnings: 2026-11-05, EPS estimate USD -2.01, revenue estimate $0K.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CRIS)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $10.6M | $10.2M | $10.0M | $10.9M | $9.4M | $4.3M |
| Operating income | -$42.1M | -$53.0M | -$48.3M | -$44.5M | -$5.7M | -$8.8M |
| Net income | -$45.4M | -$56.7M | -$47.4M | -$43.4M | -$7.6M | -$21.2M |
| EPS (diluted) | $10.00 | -$242.80 | -$179.20 | -$137.60 | -$11.60 | — |
| Free cash flow | -$37.6M | -$54.8M | -$38.4M | — | — | — |
| Operating margin | -395.0% | -521.7% | -482.2% | -408.3% | -60.5% | -203.2% |
| Net margin | -426.7% | -557.7% | -473.0% | -397.8% | -80.3% | -490.3% |
| Revenue growth | -1.7% | -4.6% | -1.4% | +8.8% | -13.4% | — |
| Cash + short-term investments | $140M | $85.6M | $56.3M | $20.0M | $5.1M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CRIS)
Superinvestors (SEC 13F-HR, Q2 2026) (CRIS)
1 of 80 tracked investors hold CRIS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Lee Ainslie | Maverick Capital | <0.01% | $6K | Unchanged |
Analysts (CRIS)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-17 | HC Wainwright & Co. | Reiterated | Buy | $43 |
| 2026-07-24 | HC Wainwright & Co. | Target raised | Buy | $17 → $43 |
Total return (dividends reinvested) (CRIS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -98.8% | -100.0% |
| S&P 500 (SPY) | +14.4% | +77.0% |
| Per year | -98.8% | -82.8% |
| Volatility (annualized) | 129.4% | 103.2% |
| Max drawdown | -98.8% (Oct 2025→Oct 2026) | -100.0% (Oct 2021→Oct 2026) |
CRIS suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Aurigene Discovery Technologies | “We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).” |
| Partner | Genentech | “In 2003, we entered into a Collaborative Research, Development and License Agreement, dated as of June 11, 2003, with Genentech, Inc. (as amended by the First Amendment to the Collaborative Research, Development and License Agreement, between us and Genentech effective as of December 10, 2004, the Second Amendment to the Collaborative Research, Development and License Agreement, between us and Genentech effective …” |
| Partner | Curis Royalty | “In connection with such transaction, we transferred to Curis Royalty all rights to Curis Technology, Inventions and Joint Patents (each as defined in the Genentech License Agreement) and assigned our rights, duties and obligations under the Genentech License Agreement to Curis Royalty.” |
Quoted from the company's 10-K filed Mar 24, 2026.
CRIS customer concentration
In the period ended Dec 31, 2025, 2 direct customers each accounted for at least 10% (100%, 100%) of revenue, per the company's 10-K filed Mar 24, 2026. The company does not name them.
CRIS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-2.01 | $-6.73 | -70.1% | $0 | 2 |
| Next quarter (ends Dec 2026) | $-1.63 | $-6.53 | -75.1% | $0 | 2 |
| Current fiscal year (ends Dec 2026) | $-23.78 | $-31.20 | -23.8% | $0 | 3 |
| Next fiscal year (ends Dec 2027) | $-6.01 | $-23.73 | -74.7% | $9.3M | 3 |
Key Statistics (as of October 23, 2026 at 14:21 UTC)
| Price | USD 0.39 |
|---|---|
| Change | ▼ 3.06% (down) |
| Previous Close | USD 0.39 |
| Open | USD 0.39 |
| Day Range | USD 0.39 – 0.42 |
| 52-Week Range | USD 0.33 – 33.6 |
| Volume | 22,477 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (CRIS)
Nexqual's technical model rates CRIS "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 14:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 8.89 (oversold) |
| vs SMA50 | Below (USD 1.05) |
| MACD | -0.25 (negative) |
Earnings (CRIS)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -2.01 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -4.02 vs est -5.21 ▲ beat |
| 2026-03-31 | USD -25 vs est -5.8 ▼ miss |
| 2025-12-31 | USD -9.95 vs est -8.65 ▼ miss |
| 2025-09-30 | USD -9.8 vs est -12 ▲ beat |
Source: Nexqual, October 23, 2026 at 14:21 UTC.
Financials & Fundamentals (CRIS)
| Total Revenue | $4.31M |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -833.40% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.22 |
| Current Ratio | 0.49 |
| Total Cash | $5.07M |
| Total Debt | $1.04M |
Source: Nexqual, October 23, 2026 at 14:21 UTC.
Ownership (CRIS)
| Insider Ownership | +3.81% |
|---|---|
| Institutional Ownership | +17.32% |
| Shares Outstanding | 2.43M |
| Float | 1.84M |
| Short % of Float | +7.46% |
Source: Nexqual, October 23, 2026 at 14:21 UTC.
From Curis, Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- In March 2025, we announced that we had completed productive meetings with both the European Committee for Medicinal Products for Human Use, or CHMP, and the FDA on the suitability of using the ongoing TakeAim Lymphoma Phase 1/2 study to support a potential accelerated regulatory path for a Conditional Marketing Authorization, or CMA, submission in Europe and a New Drug Application, or NDA, submission in the U.S.
- With passage of the FDA's Modernization Act 2.0 in December 2022, Congress eliminated provisions in both the FDCA and the Public Health Service Act, or PHSA, that required animal testing in support of an NDA.
- FDA regulations allow access to investigational drugs under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the drug under a treatment protocol, or Treatment IND Application.
- Our policy is to obtain and enforce the patents and proprietary technology rights that are key to our business.
Partnerships
- In conjunction with the October 2016 exercise of our option to license the PD-L1/TIM3 program under our collaboration with Aurigene and the March 2018 exercise of our option to the fourth program in immuno-oncology, we obtained world-wide (except for India and Russia) exclusive licenses to the Aurigene intellectual property relevant to the program.
- We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).
Legal & Regulatory Risks (Item 1A, quoted)
- Product liability lawsuits against us or our collaborators could divert our resources, cause us to incur substantial liabilities and limit commercialization of any drugs that we may develop.
- Our collaborators may utilize our intellectual property rights in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights, or expose us to potential liability.
- We face risks relating to the enforcement of our intellectual property rights in China and India that could adversely affect our business.
- We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 88.98 | ▼ 2.11% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 305.01 | ▼ 0.91% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 13.63 | ▼ 3.64% |
| PRAX | Praxis Precision Medicines, Inc | USD 251.12 | ▼ 3.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 42.71 | ▼ 2.73% |
| ABVX | Abivax SA | USD 87.52 | ▼ 3.01% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 14:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt